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Abstract
Background Approximately one in five persons living in
the USA is maintained on oral anticoagulation. It has
typically been recommended that anticoagulation be
withheld prior to hemorrhoidal procedures. Transanal
hemorrhoidal dearterialization (THD) is a minimally
invasive treatment for symptomatic hemorrhoids, and
outcomes with patients on anticoagulation who have
undergone this procedure have not been previously repor-
ted. Here, we report our preliminary results of patients who
underwent THD while on anticoagulation.
Methods During a 53-month period (February 2009–July
2015), patients with symptomatic hemorrhoids refractory
to medical management who underwent surgical treatment
with THD were retrospectively reviewed. The subset of
patients who underwent THD while anticoagulated was
compared to a cohort of patient who were not taking
anticoagulation and who otherwise demonstrated normal
coagulation profiles and who did not have a known pre-
disposition to bleeding or inherited coagulopathy. The
primary study endpoint was to assess postoperative
bleeding in patients who were maintained on anticoagula-
tion before and after surgery.
Results During the 53-month study period, 106 patients
underwent the THD procedure for symptomatic hemor-
rhoids. Of these, seventy patients underwent THD without
anticoagulation therapy, while 36 patients underwent THD
while taking one or more oral anticoagulants. The post-
operative morbidity between the two cohorts was similar,
and specifically there was no statistical difference in the
rate of postoperative hemorrhage (19.4 vs. 15.7 %; odds
ratio 1.295, 95 % CI 0.455–3.688, p = 0.785). No patient,
in either cohort, required re-intervention for any reason
during the study period. Patients who underwent THD
while on anticoagulation were less likely to have recurrent
hemorrhoidal disease during the study’s 6-month median
follow-up period (2.8 vs. 7.1 %, p = 0.049).
Conclusions These preliminary data reveal that THD can
be performed on anticoagulated patients without cessation
of oral agents without increasing morbidity from postop-
erative bleeding.
Keywords THD  Anticoagulation  Postoperative
hemorrhage  Transanal hemorrhoidal dearterialization 
Hemorrhoids
Introduction
A significant proportion of the Western population is pre-
scribed maintenance anticoagulation with a variety of
agents including oral acetylsalicylic acid (ASA), warfarin,
clopidogrel, and/or direct thrombin inhibitors. Approxi-
mately one in five (19.3 %) persons living in the USA is
maintained on monotherapy with the oral antiplatelet
medication ASA [1, 2]. Among individuals aged 45–75, the
incidence is higher, with more than half (52 %) of this
population segment taking oral ASA therapy daily [2].
Clopidogrel has also become an anticoagulant of choice,
and in 2010 it was the second most prescribed drug in the
world, generating a $9 billion industry [3]. Warfarin,
although less utilized than other anticoagulants, is com-
monly administered, and a total of 1 % of the UK’s 64.1
million population is prescribed this medication annually
[4]. Combined, up to one-quarter of the adult population in
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the USA and Europe are estimated to be taking oral anti-
coagulation as monotherapy or as a multi-drug regimen
(e.g., combination of ASA and clopidogrel). Because of
this, surgeons must contend with the anticoagulated patient.
With the increasing use of synthetic, direct thrombin inhi-
bitors, e.g., argatroban (univalent), hirudin (bivalent), sur-
geons must also be able to surgically manage this subset of
patient for which reversal is not always possible [5], and
only recently andexanet alfa has been shown to reverse
factor Xa inhibitors (apixaban and rivaroxaban) when given
minutes after administration of these anticoagulants [6].
The frequent use of anticoagulation has likely led to an
increased incidence of patients presenting with clinically
significant internal hemorrhoidal bleeding. When medically
refractory, surgeons must consider invasive procedures and
surgery to resolve patient symptoms, and in some instances
the cessation of anticoagulation or dose reduction is not safe.
One in 20 Americans and almost one-half of persons older
than 50 experience hemorrhoidal symptoms during their
lifetime, and surgical intervention is often required [7, 8]. It is
recommended that anticoagulation—including ASA—be
withheld for 7 days prior to office-based procedures, such as
hemorrhoidal banding, or surgical interventions, such as
hemorrhoidectomy and especially procedure for prolapsed
hemorrhoids (PPH) [9, 10]. The risk of significant bleeding
after hemorrhoidal banding, although uncommon, has been
well documented [11–13]. Post-hemorrhoidectomy bleeding
also occurs, to a lesser degree—approximately 1 % of the
time [14]—range 0.5–2.0 % [15]. In one series, among the
patients who had post-hemorrhoidectomy bleeding, 37 %
were on maintenance anticoagulation [15]. For these reasons,
most surgeons and society guidelines recommend that anti-
coagulation be held prior to hemorrhoidal surgery and pro-
cedures. However, whether or not this is mandatory for all
types of hemorrhoidal procedures has not been fully studied.
Transanal hemorrhoidal dearterialization (THD) is a rela-
tively recent minimally invasive treatment for symptomatic
hemorrhoids and may have important advantages over con-
ventional hemorrhoidectomy [16–18]. Its application toward
the control of rectal outlet bleeding has been previously
realized [19]. However, outcomes with patients on antico-
agulation who have undergone THD have not been previ-
ously reported, to our knowledge. Here, we report our
preliminary results of patients who underwent THD while on
anticoagulation and compared them to a cohort of patients
who underwent THD without anticoagulation.
Materials and methods
During a 53-month period (February 2009–July 2015),
patients with symptomatic hemorrhoids refractory to medi-
cal management who underwent surgical treatment with
THD were retrospectively reviewed. The study was per-
formed with internal review board (IRB) approval [Florida
Hospital, Orlando, FL USA, IRB #670312-2], and all THD
operations were performed at a single hospital system. The
data were collected, tabulated, and placed into a prospective
database, which was then analyzed retrospectively.
Under the study protocol, patients taking oral antico-
agulation medications continued taking these medications
before and after the procedure, but anticoagulation was
held on the day of surgery. Exclusion criteria included
patients on warfarin with an international normalized ratio
(INR) greater than 3X normal and patients with a platelet
count measuring\10,000, known inborn error of metabo-
lism with coagulopathy due to genetic mutation, age\18
or[95, and severe comorbidity (ASA IV, or higher).
The subset of patients who underwent THD while
anticoagulated was compared to patient who were not
taking anticoagulation and who otherwise demonstrated
normal coagulation profiles (PT, PTT, INR, and PLT) and
who did not have a known predisposition to bleeding or
inherited coagulopathy. Indication for THD was the same
in both cohorts. The indications were medically refractory
hemorrhoidal disease in patients who failed to respond to
standard conservative therapy, including dietary changes
and topical corticosteroid application in combination with
(a) persistent, clinically significant rectal outlet hemor-
rhage and/or (b) grade III hemorrhoidal prolapse in more
than one hemorrhoidal column according to the Goligher
classification system [20]. The primary study endpoint was
to assess postoperative bleeding in patients who were on
anticoagulation. The secondary endpoint was control of
hemorrhoidal disease with THD.
Surgical technique
THD was performed in a standardized fashion with figure-of-
eight ligation using absorbable suture under Doppler guidance
at six positions correlating with the odd numbers of the clock
in the patient positioned in dorsal lithotomy. No fewer than 6
ligations were performed on each patient, but if a Doppler
signal was detected after 6 ligations, then an additional suture
ligation was performed, up to a maximum of eight. Muco-
pexy was performed for all patients with prolapsing hemor-
rhoidal mucosa, and the number of columns in which
mucopexy was performed varied depending on degree and
number of hemorrhoidal columns which exhibited prolapse.
The surgical technique for THD was the same regardless of
whether or not the patients were on anticoagulation.
Statistical analysis
Data analyses were performed using the SPSS version 20.0
(SPSS Inc., Chicago, Illinois, USA). A two-sided Fisher’s
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exact test was used, and odds ratio analysis was conducted to
evaluate the differences between the two cohorts. A statis-
tical difference was denoted by p B .05, and all clinically
relevant data were evaluated in each of the two study cohorts.
Results
During the 53-month study period, 106 patients underwent
the THD procedure for symptomatic hemorrhoids. Of
these, seventy patients underwent THD without anticoag-
ulation therapy, while 36 patients underwent THD while
taking one or more oral anticoagulants, without discon-
tinuation except for the day of surgery. There was no sta-
tistical difference in the demographics of the two groups or
the hemorrhoidal grade (Table 1). However, prolapse was
more likely to be the indication for THD for the cohort of
patients not taking anticoagulation, while bleeding was
more likely to be the reason why THD was performed on
anticoagulated patients. There was no statistical difference
between median operative times, which measured 31 min
(14–102 min) for patients on anticoagulation and 28.5 min
(18–76 min) for patients off anticoagulation. Interestingly,
the median blood loss was less during THD in which
patients were anticoagulated, with 15 ml (5–15 ml) vs.
20 ml (2–100 ml) for patients not on anticoagulation,
p = 0.03. The postoperative morbidity between the two
cohorts was similar, and specifically there was no statistical
difference in the rate of postoperative hemorrhage (19.4 vs.
15.7 %; odds ratio 1.295, 95 % CI 0.455–3.688,
p = 0.785) (Table 2). Of the 7 patients who presented with
postoperative bleeding in the anticoagulated cohort, two re-
presented to the emergency center. One of these presen-
tations was on postoperative day 11 in a 73-year-old male
on apixaban monotherapy, while the other was on post-
operative day seven in a 73-year-old male who was on
monotherapy with 81 mg ASA. Neither patient required re-
intervention, admission, or transfusion as these were self-
limited bleeding events that resolved without therapy. The
remaining 5 patients only reported self-limited bleeding on
their 4-week follow-up appointment. No patient, in either
cohort, required re-intervention for any reason during the
study period. Patients who underwent THD while on
anticoagulation were less likely to have recurrent hemor-
rhoidal disease during the study’s 6-month (3–24 months)
median follow-up period (2.8 vs. 7.1 %, p = 0.049).
The type of anticoagulation varied and is detailed in
Table 3. The most common type of anticoagulation was
once daily oral 81 mg ASA with 20/36 (55.6 %) taking this
medication once daily. Of the seven patients in the
THD ? anticoagulation group who experienced bleeding in
the postoperative period, only two were on ASA
monotherapy, while 5/7 were taking warfarin as monother-
apy or dual anticoagulation therapy in combination with
either fondaparinux, enoxaparin, or apixaban (Table 3).
Discussion
The approach to the treatment of hemorrhoidal disease
remains individualized, and management often requires the
ability to provide a spectrum of interventions based on
Table 1 Clinical characteristics
of patients undergoing THD
THD on anticoagulation (%) THD off anticoagulation (%) p value
n 36 70
Age (range)a (years) 64 (35–79) 48 (22–86) NS
Male/female 2.6:1 1.6:1
BMIa 28 (24–35) 27 (23–33) NS
Grade of hemorrhoidb
Grade 1 5 (13.8) 10 (14.2)
Grade 2 17 (47.2) 35 (50.0)
Grade 3 13 (36.1) 24 (34.2)
Grade 4 1 (2.7) 1 (1.4)
Presenting preoperative symptoms
Bleedingc 33 (86.8) 49 (73.1) 0.006
Prolapsec 9 (25.0) 27 (38.5) 0.0004
Otherc 10 (26.3) 8 (11.9) NS
THD Transanal hemorrhoidal dearterialization, BMI Body mass index expressed in kg/m2
a Age and BMI reported as median (range)
b Grade of hemorrhoid and presenting symptoms reported in absolute value. Patients reported by preop-
erative graded severity of hemorrhoids according to Goligher’s classification
c Presenting preoperative symptoms (bleeding, prolapse, and other) reported as absolute values
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extent, chronicity, and pathoanatomy. But treatment must
also be tailored to a given patient in the context of clinical
parameters, which commonly—and importantly—include
the requirement for anticoagulation [21, 22]. This is a key
component of the surgeon’s decision matrix when deter-
mining how to proceed with intervention, once surgery is
considered a necessary pathway toward ameliorating
hemorrhoidal symptoms. Physicians and surgeons under-
stand that some patients present an increased risk of
thromboembolic or cardiac events when anticoagulation is
held—even temporarily. In the ROCKET AF trial, 4.8 %
of patients experienced gastrointestinal (GI) bleeding and
29 % rectal origin [23]; however, the risk of gastroin-
testinal bleeding related to novel oral anticoagulants
appears similar to that of warfarin [24].
Furthermore, there is a risk of so-called rebound
hypercoagulability in patients who undergo cessation of
anticoagulants and then restart them, thus increasing the
risk of adverse thrombotic events [25–27]. For patients
with bare-metal or drug-eluting stents [28, 29], prosthetic
heart valves [30, 31], recent prosthetic peripheral arterial
grafts [32], and recent thromboembolic events [33], the risk
of anticoagulant cessation can be significant. Thus, for
select patients, the surgeon must estimate the procedural
bleeding risk and weigh this against the estimated throm-
boembolic or cardiac event risk when deciding whether or
not anticoagulation can be safely interrupted, and whether
or not bridging is required [34–40].
In this study, it is demonstrated that the incidence of
hemorrhage requiring intervention after THD is not sta-
tistically different between anticoagulated and non-anti-
coagulated patient cohorts undergoing the procedure.
These early data suggest that THD could be a safe opera-
tion for anticoagulated patients, which is an important
clinical demographic confronting colorectal surgeons.
However, the authors recognize important limitations of
this study, which are principally the small sample size and
the retrospective non-randomized nature of the study
design. A blinded, randomized trial in which patients
already on anticoagulation were assessed for the morbidity
of postoperative hemorrhage and also thromboembolic
events would be necessary to support or refute the validity
of performing THD on patients on systemic anticoagula-
tion therapy. Furthermore, the study is limited by the
heterogeneity of the types of anticoagulation agents, and
because the majority (55.6 %) of the anticoagulated cohort
were on monotherapy with low-dose, oral 81 mg ASA.
Since complications of aspirin treatment increase propor-
tionally with dose, the results of the present study may not
reflect the complication rate of patients taking moderate
(100–200 mg/day) or high ([200 mg/day) doses [41].
Notwithstanding, in this study only two patients (5.6 %) in
the anticoagulated cohort presented for medical evaluation
Table 2 Operative outcomes
for patients undergoing THD
THD on anticoagulation (%) THD off anticoagulation (%) p values
OR timea 31 (14–102) 28.5 (18–76) NS
EBLa 15 (5–50) 20 (2–100) 0.03
ASA scorea 2.2 1.4
Mucopexyb 33 (91.7) 54 (77.1) 0.019
Postop morbidity
Bleedingb 7 (19.4) 11 (15.7) NS
Painb 7 (19.4) 9 (12.8) NS
Urinary retentionb 1 1 NS
Recurrenceb 1 (2.8) 5 (7.1) 0.049
THD Transanal hemorrhoidal dearterialization, OR time Median operating time in minutes (range); EBL
Median estimated blood loss in milliliters (range); ASA American Society of Anesthesiologists score
reported as mean
a values reported in median (range)
b Mucopexy, bleeding, pain, urinary retention, and recurrence reported in absolute value (percent); NS Not
significant
Table 3 List of specific anticoagulation medications for patients who





Aspirin 81 mg 20 1




Apixaban ? warfarin 1 1
Fondaparinux ? warfarin 1 1
Enoxaparin ? warfarin 1 0
Aspirin/dipyridamole 1 0
Total 36 7
THD Transanal hemorrhoidal dearterialization
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after THD at an emergency center, but neither required
transfusion, surgical intervention, or other specific therapy
and were categorized as self-limited postoperative hemor-
rhage. Thus, for high-risk cardiovascular patients the need
to bridge with low molecular weight heparin as a bridge to
surgery may be obviated by using THD procedure—with-
out significantly increasing the risk of postoperative
bleeding.
Because patients with cardiovascular disease are often
recommended to remain on anticoagulation to maintain
homeostasis and also to prevent the described phenomenon
of rebound hypercoagulability, surgeons must often tailor
the approach to hemorrhoidal disease based on these fac-
tors which can restrict the safe and permissible options to
manage hemorrhoidal disease. For example, many experts
do not recommend hemorrhoidal band ligation for antico-
agulated patients unless the anticoagulation has been held
prior to (and after) hemorrhoidal ligation [42, 43]. Like-
wise, excisional hemorrhoidectomy mandates that antico-
agulation be held due to the increased risk of significant
bleeding postoperatively. THD could be a ‘middle ground’
between less invasive procedures such as hemorrhoidal
band ligation and excisional procedures (Ferguson or
Milligan–Morgan) for hemorrhoidal treatment, for
which—as these data suggest—the cessation of oral anti-
coagulation may not be necessary.
Conclusions
These preliminary data suggest that THD can be performed
on anticoagulated patients without cessation of oral agents
without increasing the morbidity from postoperative
bleeding. Although encouraging, the small sample size
limits the overall generalizability of the study findings, and
further investigation is necessary prior to concluding that
THD should be routinely performed without prerequisite
cessation of oral anticoagulants.
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